Frequently associated with obesity, NAFLD where fat is deposited in the liver affects about one third of the adult population worldwide. In 25% of those patients, NAFLD will progress to NASH leading to inflammation and damage. Currently, there is no single reliable biochemical marker that can diagnose NAFLD or its progression to NASH and there are few treatment options other than palliative support or liver transplantation. Diagnostic markers to accurately identify patients with NAFLD and NASH are urgently needed to provide cost-effective care.
"One of the goals of our project is to identify new and valuable disease 'predictors' or biomarkers that will allow physicians to better understand and predict the progression of NAFLD and NASH," explains Dr. Nilsson who is also Director of Proteomics at The McGill University and Genome Quebec Innovation Centre. "These predictors could form the basis of new diagnostic tests or treatment options. If successful in liver disease, the methods used here could be applied to other complex diseases."
This program will provide an excellent training opportunity for a new generation of scientists and clinicians in advanced techniques in molecular and cell biology and bioinformatics.
In addition to Dr. Tommy Nilsson (RI-MUHC/McGill), Dr. Peter Metrakos (MUHC/McGill), Dr. John Bergeron (RI-MUHC/McGill), Dr. Rob Sladek (RI-MUHC/McGill), Dr. Silvia Vidal (RI-MUHC/McGill), Dr. Rima Rozen (RI-MUHC/McGill), Dr. Barry Posner (RI-MUHC/McGill), Dr. Vassilios Papadopoulos (RI-MUHC/McGill) and colleagues from MUHC and McGill participated in this research program.
|Contact: Julie Robert|
McGill University Health Centre